MAPT and Cognitive impairment: These studies provide experimental evidence showing the possible mechanisms by which CCH can contribute to cognitive impairment and AD probably through reduction of protein O-GlcNAcylation, hyperphosphorylation of tau, dysregulated synaptic plasticity and neural degeneration in the brain.